Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TNFRSF8 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	Acute Myelogenous Leukemia	TNFRSF8 expression	Acute Myelogenous Leukemia	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1
TNFRSF8 expression	Diffuse Large B Cell Lymphoma	TNFRSF8 expression	Diffuse Large B Cell Lymphoma	rituximab + brentuximab vedotin Sensitive: C3 – Early Trials rituximab + brentuximab vedotin Sensitive : C3	rituximab + brentuximab vedotin Sensitive: C3 – Early Trials rituximab + brentuximab vedotin Sensitive : C3
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	AFM13 Sensitive: C3 – Early Trials AFM13 Sensitive : C3	AFM13 Sensitive: C3 – Early Trials AFM13 Sensitive : C3
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Hodgkin Lymphoma	TNFRSF8 expression	Hodgkin Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Hematological Malignancies	TNFRSF8 expression	Hematological Malignancies	F0002-ADC Sensitive: D – Preclinical F0002-ADC Sensitive : D	F0002-ADC Sensitive: D – Preclinical F0002-ADC Sensitive : D
TNFRSF8 expression	Lymphoma	TNFRSF8 expression	Lymphoma	PF-08046044 Sensitive: D – Preclinical PF-08046044 Sensitive : D	PF-08046044 Sensitive: D – Preclinical PF-08046044 Sensitive : D